Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
A phase 1/2 trial of Pembrolizumab, Ipilimumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Vyriad, Inc., active and no longer recruiting.
Overview
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors is a phase 1/2 interventional study registered as NCT03647163 by Vyriad, Inc., with 33 participants enrolled, started 2019-04-09 and due to reach its primary completion in 2025-07-31. Interventions recorded: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab. Conditions listed: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Ipilimumab, Nivolumab, Pembrolizumab.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.